Võrdle meetodeid

	Mayo aktiivsusindeks haavandilise koliidi korral	Lühike põletikulise soolehaiguse küsimustik
Valdkond	Gastroenteroloogia	Gastroenteroloogia
Perekond	Process / pipeline	Process / pipeline
Tekkeaasta	1987	2004
Looja	Schroeder, K. W., Tremaine, W. J., and Ilstrup, D. M.	Guyonnet, D., Chassany, O., Ducroc, R., et al.
Tüüp	Clinician-rated	Self-report
Algallikas	Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987). Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. New England Journal of Medicine, 317(26), 1625–1629.	Guyonnet, D., Chassany, O., Ducroc, R., Picard, C., Mouret, M., D'Haens, G., & Svartz, H. (2004). Effect of fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in France: A multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics, 20(4), 459–465.
Rööpnimetused	Mayo Clinic Score, UC Mayo Score	IBDQ-32, Short IBDQ
Seotud	4	4
Kokkuvõte	The Mayo Score is a validated tool for assessing disease activity in ulcerative colitis, integrating clinical symptoms and endoscopic findings. Introduced by Schroeder and colleagues in 1987, it has become the reference standard for UC activity assessment in clinical trials and practice. The score combines stool frequency, rectal bleeding, overall physician global assessment, and endoscopic subscore into a single 0–12 scale.	The Short Inflammatory Bowel Disease Questionnaire (IBDQ-32) is a validated patient-reported outcome measure designed to assess the impact of inflammatory bowel disease (IBD)—both ulcerative colitis and Crohn's disease—on health-related quality of life. Derived from the original 32-item IBDQ, this instrument comprises four domains: Bowel Symptoms, Systemic Symptoms, Social Function, and Emotional Function. The IBDQ-32 is responsive to treatment and is increasingly used in IBD clinical trials and practice.